Table 3 Patients with adverse events during the double-blind phase (treated patients population)
n (%) | Saxagliptin + Metformin (n = 74) | Placebo + Metformin (n = 86) |
|---|---|---|
Any AE | 19 (25.7) | 34 (39.5) |
Treatment-related AE | 1 (1.4) | 3 (3.5) |
SAE | 1 (1.4) | 1 (1.2) |
Treatment-related SAE | 0 | 0 |
Discontinuation due to AE or SAE | 0 | 0 |
Death | 0 | 0 |